- Home
- MIRM vs CAMT Comparison
MIRM vs CAMT Comparison
Compare MIRM & CAMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- CAMT
- Stock Information
- Founded
- MIRM 2018
- CAMT 1987
- Country
- MIRM United States
- CAMT Israel
- Employees
- MIRM N/A
- CAMT N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- CAMT Electronic Components
- Sector
- MIRM Health Care
- CAMT Technology
- Exchange
- MIRM Nasdaq
- CAMT Nasdaq
- Market Cap
- MIRM 3.8B
- CAMT 3.8B
- IPO Year
- MIRM 2019
- CAMT 2000
- Fundamental
- Price
- MIRM $72.65
- CAMT $123.82
- Analyst Decision
- MIRM Strong Buy
- CAMT Strong Buy
- Analyst Count
- MIRM 11
- CAMT 11
- Target Price
- MIRM $79.00
- CAMT $108.00
- AVG Volume (30 Days)
- MIRM 560.3K
- CAMT 491.3K
- Earning Date
- MIRM 11-04-2025
- CAMT 11-10-2025
- Dividend Yield
- MIRM N/A
- CAMT 1.07%
- EPS Growth
- MIRM N/A
- CAMT 38.64
- EPS
- MIRM N/A
- CAMT 2.73
- Revenue
- MIRM $429,161,000.00
- CAMT $471,588,000.00
- Revenue This Year
- MIRM $53.14
- CAMT $17.22
- Revenue Next Year
- MIRM $19.83
- CAMT $8.51
- P/E Ratio
- MIRM N/A
- CAMT $45.32
- Revenue Growth
- MIRM 62.33
- CAMT 27.88
- 52 Week Low
- MIRM $36.88
- CAMT $47.41
- 52 Week High
- MIRM $78.55
- CAMT $129.41
- Technical
- Relative Strength Index (RSI)
- MIRM 52.77
- CAMT 59.94
- Support Level
- MIRM $68.34
- CAMT $116.16
- Resistance Level
- MIRM $71.96
- CAMT $129.41
- Average True Range (ATR)
- MIRM 2.53
- CAMT 4.86
- MACD
- MIRM -0.13
- CAMT -0.50
- Stochastic Oscillator
- MIRM 56.54
- CAMT 65.64
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About CAMT Camtek Ltd.
Camtek Ltd is engaged in the manufacturing of metrology and inspection equipment and software solutions for the semiconductor industry. Its systems inspect wafers for various semiconductor market segments, including Advanced Packaging, Heterogenous Integration (HI), Compound Semiconductors, Memory, and foundries among others. Geographically, it derives maximum revenue from China followed by Asia Pacific, Korea, United States, and Europe. The company's products and services include Surface Inspection, Bump Inspection and Metrology, and others.